business
South Korea's Samsung Biologics Bids CHF1.5 Billion for Swiss Pharma Supplier Polypeptide
In a major development for the Swiss pharmaceutical sector, South Korean contract manufacturer Samsung Biologics has submitted a CHF1.5 billion cash offer to acquire Polypeptide, a key Swiss producer of active pharmaceutical ingredients.
about 2 months ago · 1 source
